Nefazodone-d6 (dihydrochloride)

• UNSPSC Description:

  Nefazodone-d6 (dihydrochloride) is deuterium labeled Nefazodone (hydrochloride). Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].

• Target Antigen:

  5-HT Receptor; Adrenergic Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease; Endocrinology

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(C([2H])([2H])C([2H])([2H])C([2H])([2H])N2CCN(C3=CC=CC(Cl)=C3)CC2)N=C(CC)N1CCOC4=CC=CC=C4.Cl.Cl

• Molecular Weight:

  548.97

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Ellingrod VL, et al. Nefazodone: a new antidepressant. Am J Health Syst Pharm. 1995;52(24):2799-2812.|[3]Pullar IA, et al. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol. 2000;407(1-2):39-46.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported